A Primer on PAMA
The impending legislation that may determine Medicare lab fees from 2025 onward
The impending legislation that may determine Medicare lab fees from 2025 onward
Proper usage of ABN-related modifiers is a significant issue that has a direct impact on your lab’s reimbursement and compliance.
Lab leaders must be able to make a sound assessment of both the costs and benefits, and the liability risks involved.
Labs have a duty to inquire into what their billing company is up to and whether it complies with all applicable regulations.
How to explain the current state of EKRA to your lab executives.
Here are the changes to Medicare specimen collection fee and travel allowances included in the 2023 PFS and what you’ll need to know to comply.
One of the biggest danger areas that labs and their billing staffs face in COVID-19 test reimbursement is improper use of HCPCS code G2023.
What labs and billing managers need to know about multianalyte assays with algorithmic analyses coding for tests based on molecular platforms.
An overview and general briefing on some of the most common ICD codes concerns for labs.
Due to the common misuse of this modifier, the Centers for Medicare & Medicaid Services recently issued important new guidance on its proper use.
Completing the Advance Beneficiary Notice of Noncoverage form can be extremely complex; this guide helps simplify the process.